Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Recommended Reading A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology An experimental medicine from a small biotechnology company cut the risk of lung cancer ...

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

By creating more effective, transparent ad transactions, DV strengthens the digital advertising ecosystem, ensuring a fair value exchange between buyers and sellers of digital media.

There are three ways to make image backgrounds transparent on Mac: Using Remove background in Tools, Instant Alpha, and Selection tools. Before following any of the methods given below, make a ...

It is going to look a little bizarre, but there is a great reason behind the change… Nike have changed their logo on third kits to celebrate women's football. They explained their switch for ...

The best free logo maker lets you create eye-catching graphics to market your business completely free. Our team of creatives tested out the best logo makers and the best graphic design software ...

Merck MRK decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer ...

A Reddit thread started Thursday titled, "What's wrong with the Facebook logo?" shows a blue lowercase "f" on a black background instead of a blue background with a white "f." Some users who have ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

Mer­ck said Thurs­day morn­ing it is dis­con­tin­u­ing two Phase 3 tri­als of Keytru­da, the world’s top-sell­ing med­i­cine, af­ter in­de­pen­dent da­ta mon­i­tor­ing … ...